Incidence and risk factors for hyperglycemia in pregnancy among nulliparous women: A Brazilian multicenter cohort study by Nicolosi, Bianca F et al.
RESEARCH ARTICLE
Incidence and risk factors for hyperglycemia
in pregnancy among nulliparous women: A
Brazilian multicenter cohort study
Bianca F. Nicolosi1, Renato T. Souza2, Jussara Mayrink2, Francisco E. Feitosa3, Edilberto
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To assess the incidence and risk factors for hyperglycemia in pregnancy in a cohort of Bra-
zilian nulliparous pregnant women.
Materials and methods
This is a secondary analysis of a multicenter cohort study that enrolled 1,008 nulliparous
pregnant women at 19–21 weeks. Exclusion criteria included chronic exposure to corticoste-
roids and previous diabetes. Bivariate and multivariate analyses by Poisson regression
were used to identify associated factors.
Results
The incidence of hyperglycemia in pregnancy was 14.9% (150/1,008), and 94.7% of these
cases were gestational diabetes mellitus (142/150). Significant associated factors included
a family history of diabetes mellitus, maternal overweight or obesity at enrollment, and previ-
ous maternal conditions (polycystic ovarian syndrome, thyroid dysfunctions and hyperten-
sive disorders). A BMI� 26.3Kg/m2 (RRadj 1.87 [1.66–2.10]) and a family history of diabetes
mellitus (RRadj 1.71 [1.37–2.15]) at enrollment were independent risk factors for HIP.
Conclusions
A family history of diabetes mellitus and overweight or obesity (until 19–21 weeks of gesta-
tion) may be used as selective markers for HIP in Brazilian nulliparous women. Given the
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scarcity of results in nulliparous women, our findings may contribute to determine the opti-
mal diagnostic approach in populations of similar socioeconomic characteristics.
Introduction
The International Association of Diabetes and Pregnancy Study Group (IADPSG) and the
International Federation of Gynecology and Obstetrics (FIGO) divided hyperglycemia in preg-
nancy (HIP into two distinct conditions: Diabetes in pregnancy (DIP) and Gestational Diabe-
tes Mellitus (GDM). DIP is defined as diabetes diagnosed before pregnancy o hyperglycemia
with first recognition during pregnancy according to WHO diagnostic criteria for non-preg-
nant women that may occur at any time during pregnancy including the first trimester. GDM
is defined as pregnancy related hyperglycemia (other than DIP) OR hyperglycemia with first
recognition during pregnancy that may also occur at any time during pregnancy, but most
likely occurs after 24 weeks of gestation [1–4].
According to the FIGO, HIP is one of the most common complications in pregnancy due
to the epidemic of obesity and diabetes, also referred to as the DIABESITY epidemic. HIP is
estimated to affect one in six pregnant women and 84% of them are GDM. Brazil is one of the
eight low- and middle-income countries contributing to 55% of global live births and 55% of
the global burden of diabetes [1–4]. According to the Brazilian Gestational Diabetes Study
(EBDG), a multicenter cohort that included 5,564 Brazilian pregnant women, the estimated
prevalence of GDM was 18% according to the IADPSG criteria [5].
A recent Brazilian consensus recommended universal screening with fasting plasma glucose
(FPG) and a 75-g oral glucose tolerance test (OGTT) in settings where technical and financial
resources are available, identifying 100% of GDM cases. In suboptimal settings, a normal FPG
(< 92 mg/dL) at the first antenatal visit, and screening repeated at 24–28 weeks of gestation
can identify 86% of GDM cases [6].
The previous consensus document from WHO initially led to a policy of universal screen-
ing [3], however, this resulted in the diagnosis of GDM in a growing number of women, with-
out sufficient evidence of improvement in maternal/neonatal outcomes or cost-effectiveness.
Therefore, controversy persists over whether to screen for GDM. Several clinical and biomo-
lecular risk factors have already been tested, either alone or in algorithms. The predictive per-
formance of these markers has actually been poor, due to low prevalence rates and population-
dependent variations in risk factors. Furthermore, there is a diversity of suggested diagnostic
criteria for GDM across studies [7–9].
The identification of risk factors in a particular population of pregnant women, along with
a well-defined diagnostic protocol, may improve the performance of risk factors in predicting
HIP (DIP or GDM). Although several studies have previously identified classical risk factors
for GDM, relatively few studies have been conducted in nulliparous women [10–12], and none
were focused on Brazilian healthy nulliparous women. Our objective was to assess the inci-
dence and risk factors for HIP (DIP or GDM) in a cohort of Brazilian nulliparous pregnant
women.
Materials and methods
This is secondary analysis of the Preterm SAMBA, a prospective multicenter cohort study con-
ducted from July 2015 to July 2018 in five Brazilian obstetric referral centers: the University of
Campinas (UNICAMP)/SP, Botucatu Medical School, Unesp/SP, Federal University of Ceará
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(UFC)/CE, Federal University of Pernambuco (UFP)/PE, and Federal University of Rio
Grande do Sul (UFRGS)/RS. The study protocol was approved by the Institutional Review
Board (IRB) of the School of Medical Sciences of The University of Campinas (Letter of
approval 1.048.565 issued on 28th April 2015), and all other Brazilian participating centers:
IRB from the Maternidade Escola Assis Chateaubriand of the Federal University of Ceara in
Fortaleza, IRB from the Center for Health Sciences of the Federal University of Pernambuco in
Recife, IRB from the Clinics Hospital of the Federal University of Rio Grande do Sul in Porto
Alegre, and the IRB from the Clinics Hospital of Botucatu Medical School at the University of
the State of Sao Paulo (Unesp) and amended by the Brazilian National Committee for Ethics
in Research (CONEP). The study complies with national and international regulations for
experiments in human beings, including resolution CNS 466/12 of the Brazilian National
Heath Council and the 1989 Declaration of Helsinki. Each woman signed an informed consent
form before entering the study. This manuscript follows the Strengthening the Reporting of
Observational studies in Epidemiology (STROBE) Statement [13].
Methodological details and operational procedures of the Preterm SAMBA study had
already been published elsewhere [14–16]. Briefly, the preterm SAMBA project was divided
into two phases [14–16]: 1) discovery of a predictive model based on data and samples from an
international multicenter cohort entitled SCOPE study (which included only nulliparous
women) [16]; 2) validation of the predictive model using a multicenter Brazilian cohort.
Matching the eligibility criteria of participants from the SCOPE and the Preterm SAMBA stud-
ies was crucial for developing and validating the predictive model. The validation of predictive
model, however, is not the scope of the current analysis. In addition to preterm birth, other
major pregnancy complications have been considered as secondary outcomes for the Brazilian
cohort, including hyperglycemia in pregnancy, preeclampsia, and fetal growth restriction.
Subjects
The study enrolled nulliparous singleton pregnant women from 19+0 to 21weeks of gestation.
Exclusion criteria included chronic exposure to corticosteroids and previous type 1 or type 2
Diabetes Mellitus (T1DM or T2DM) and other maternal chronic diseases and use of medica-
tions/supplements [14].
Sample size
The sample size was calculated according to spontaneous preterm birth outcome, which was
the main outcome for the cohort. Assuming a type I error of 5%, accuracy of at least 0.68 for
the test measured by the area under the ROC curve, and adequate power (80% of power, β =
0.2) to test the hypothesis, the sample size should approach 80 cases of preterm births. Consid-
ering that the expected minimum prevalence of preterm birth is 7% in Brazil, the sample size
calculated was 1,150 women. Estimating a prevalence of around 10–15% of GDM in nullipa-
rous pregnant women [17], the Preterm SAMBA study population would be able to identify
about 115 to 170 cases.
Data collection procedures
Eligible women were identified in the primary health care units and in the obstetric antenatal
clinics in the referral maternities. Women were included between 19 and 21 weeks of gestation
(first study visit), and a comprehensive assessment was conducted to gather information on
sociodemographic characteristics, reproductive history, personal and family medical history.
After the interview, anthropometric and clinical measurements, and a nutritional assessment
based on a 24-hour diet recall were performed according to standardized protocols. The same
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clinical andanthropometric evaluation was also performed during two subsequent study visits
(at 27–29 and 37–39 weeks of gestation). A review of the medical record and prenatal chart
was conducted in the postpartum period to collect maternal and newborn information related
to the late pregnancy, intrapartum and postpartum periods, in addition to newborn data [14].
The collected data had been entered in an online database system.
Data regarding the results of fasting plasma glucose from early- to mid-pregnancy was
recorded at the 19–21 weeks study visit. Data on OGTT or fasting plasma glucose dones in the
second half of pregnancy was recorded during the second and third study visits (27–29 and
37–37 weeks) and during the postpartum medical record review. Although the diagnostic pro-
tocol for HIP was previously recommended [1–4], each center employed its own diagnostic
and treatment protocol, according to physical, structural and economic conditions, as recom-
mended by the Brazilian guidelines [6]. Data were entered into a central database accessible
through the Internet, provided with a complete audit trail (MedSciNet1).
Outcome
In the current study, the outcome was hyperglycemia in pregnancy (HIP). It was divided into
two distinct forms: diabetes in pregnancy (DIP) and gestational diabetes mellitus (GDM) [1–4].
DIP was defined as diabetes diagnosed before pregnancy or hyperglycemia with first recognition
during pregnancy according to WHO diagnostic criteria for non-pregnant women, and diag-
nosed by fasting plasma glucose� 7.0 mmol/L (126 mg/dL) or 2-hour plasma glucose� 11.1
mmol/L (� 200 mg/dL) following a 75g OGTT or a random plasma glucose� 11.1 mmol/L
(� 200 mg/dL) with diabetes symptoms [1–4]. GDM was defined as hyperglycemia (other than
DIP) during pregnancy or hyperglycemia with first recognition during pregnancy. GDM diag-
nostic criteria were fasting plasma glucose� 5.1 and� 6.9 mmol/L (� 92 and� 125 mg/dL) or
1-hour plasma glucose� 10.0 mmol/L (� 180 mg/dL) following a 75g OGTT or a 2-hour plasma
glucose� 8.5 and� 11.0 mmol/L (� 153 and� 199 mg/dL) following a 75g OGTT [1–4].
Risk factors associated with HIP
The following sociodemographic and maternal clinical characteristics were addressed as potential
risk factors for HIP: maternal age� 25 years, non-white ethnicity, marital status (without a part-
ner), schooling< 12 years, lower annual family income, source of prenatal care (public health ser-
vices), reproductive and family history of diabetes–first-degree relatives with DM and pregnant
woman whose mother had GDM during her pregnancy, smoking and alcohol habits, maternal
weight gain (WG) at 20–27 weeks of gestation, body mass index (BMI) at study enrollment, any
previous disorders (polycystic ovarian syndrome, thyroid dysfunction, previous hypertensive dis-
order), and blood pressure at 20 weeks of gestation were evaluated. Likewise, we evaluated some
maternal and neonatal outcomes commonly described for women with HIP [7–9].
The proportion of women in each quartile (below Q1, Q1-Q2, Q2-Q3 and above Q3) and
percentile category (< p10, p10-p90, and> p90) of weight gain per week between the first and
second visit were also addressed for both HIP and control groups. Due to the difficulty in
obtaining information on pre-gestational weight, maternal weight at the first visit (19–21
weeks of gestation) was defined as the reference for estimation of WG from 20 to 27 weeks of
gestation and BMI at enrollment, classified according to the new references for Brazilian preg-
nant women [18].
Statistical analysis
Initially, we determined the incidence of HIP, the absolute and relative incidence of its compo-
nents (DIP and GDM), and the frequency of abnormal 75g-OGTT results to offer treatment.
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To compare HIP and control (Non-HIP), we assessed potential risk factors, along with associ-
ated maternal and neonatal outcomes. A bivariate analysis was carried out to estimate Risk
Ratios (RR) and their respective 95% Confidence Intervals (95%CI). Finally, a multivariate
analysis was performed, using Poisson multiple regression with backward selection, to identify
which factors were independently associated with HIP and estimate the adjusted RR (RRadj).
Data analysis was adjusted for the Primary Sampling Unit (PSU) of the five centers/hospitals
(p< .05). We used SPSS v20.0 and Stata v7.0 software.
Results
Fig 1 shows the study flow chart defined according to outcome–Hyperglycemia diagnosed
during pregnancy (HIP), comprising Diabetes in Pregnancy (DIP) and Gestational Diabetes
Mellitus (GDM). Table 1 shows the incidence of HIP (14.9%), with their components–DIP
(0.8%) and GDM (14.1%), in Brazilian low-risk, nulliparous pregnant women, included in the
Preterm SAMBA cohort. Of the 150 pregnant women diagnosed with HIP, 58 (38.7%) received
no treatment and 92 (61.3%) were treated with diet and exercise alone (21.7%) or received
adjuvant drugs (insulin or metformin) (78.3%).
Family history of DM [RR = 1.86; 1.50–2.30], overweight [RR = 1.49; 1.27–1.76], obesity
[RR = 2.16; 1.57–2.96], and previous disorders (POS, thyroid dysfunction or hypertension)
[RR = 1.81; 1.05–3.13] were significantly associated with the occurrence of HIP (Tables 2 and
3). In this cohort, maternal or perinatal outcomes were not significantly different in the HIP
group as compared to the Control group (Table 4).
Multivariate analysis showed that a BMI� 26.3Kg/m2 [RRadj = 1.87; 1.66–2.10] and a fam-
ily history of DM [RRadj = 1.71; 1.37–2.15] at study enrollment were independent factors asso-
ciated with HIP (Table 5).
Discussion
In low-risk nulliparous pregnant women included in the Preterm SAMBA Brazilian cohort,
the prevalence ofof HIP was14.9% of which 94.7% wasGDM and 5.3% was DIP. A family his-
tory of DM, overweight, obesity and previous conditions including polycystic ovarian syn-
drome (POS), thyroid dysfunctions and hypertensive disorders were identified as factors
associated with HIP. However, only a BMI� 26.3Kg/m2 and a family history of DM at study
enrollment were shown to be independent risk factors for HIP.
The high incidence of GDM in our Brazilian cohort is not surprising. In a recent study con-
ducted in Finland, 16.5% of the nulliparous women evaluated were diagnosed with gestational
diabetes [10]. This result is in line with our findings, but lower rates have also been reported.
In Ireland and in the United Kingdom the incidence of GDM was 8.9% in nulliparous women
at risk and 7.7% in those who are not at risk for the condition. In Australia, only 4.8% of the
nulliparous investigated women had GDM [11,12]. The criteria for GDM and HIP, nutri-
tional/diet habits and the characteristics of the population, especially the prevalence of obesity,
are the main reasons for the disparities on the prevalence of HIP in the different populations.
The incidence of HIP among nulliparous women is of public health concern. It has been esti-
mated that a woman with GDM in her first pregnancy has a 50% risk of GDM recurrence in
her second pregnancy [19]. Since Brazil is one of the eight countries responsible for 55% of
deliveries and 55% of diabetes cases worldwide [1], having a GDM rate of 14.9% in nulliparous
women makes matters even worse. Thereby, there is an urgent need for the early prediction,
diagnosis and treatment of HIP.
Maternal age, ethnicity, pregestational BMI, family history of DM, previous GDM and
macrosomia, multiparity and hypertension are well-established clinical risk factors for GDM
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[7–9,20]. However, the prevalence of overweight and obesity epidemic in women of childbear-
ing age contributes to a higher risk of GDM [20,21–24]. Only few studies have actually reported
risk factors for GDM in nulliparous women [10–12,25]. In Brazilian nulliparous women, these
risk factors have still not been published. Therefore, our study may help to address this deficit.
Risk-based screening is controversial. While some authors consider this type of screening
inadequate and inconsistent, others support that offering an OGTT to women aged� 25 years
old and/or with a BMI� 26.3kg/m2 is as effective as more complex risk prediction models
[9,26,27–29]. In our nulliparous Brazilian cohort, overweight or obesity and a family history of
DM were independent risk factors for HIP.
In our cohort study, a family history of DM occurred in 31.3% of HIP and in 17.7% of the
control group. These rates thus differed between pregnant women with and without GDM,
and were lower than previously published–rates of about 40 to 50% in the GDM group and 35
Fig 1. Flow chart of participating women in the study.
https://doi.org/10.1371/journal.pone.0232664.g001
PLOS ONE Risk for hyperglycemia in nulliparous pregnancy
PLOS ONE | https://doi.org/10.1371/journal.pone.0232664 May 13, 2020 6 / 14
to 40% in the control group [12,29]. This finding may contribute to the discrepancy between
our results and other reports in the literature.
In Brazilian nulliparous women, a BMI� 26.3Kg/m2 at 19 to 21 weeks of gestation should
be highlighted. In our study, the risk of developing HIP increased almost twofold in over-
weight or obese women. Irrespective of parity, a systematic review showed that the risk for
GDM rises progressively according to BMI category [30]. Several studies have previously
shown an association between the degree of maternal adiposity and hyperglycemia, while oth-
ers have identified that maternal age is the modulating factor [17,20–23,30–32]. In nulliparous
Table 1. Diagnosis of hyperglycemia in pregnancy (HIP) in nulliparous Brazilian cohort study.









Diet and exercise alone 72/92 78.3
Drugs (insulin or metformin) 20/92 21.7
HIP = Hyperglycemia in Pregnancy; GDM = Gestational Diabetes Mellitus; DIP = Diabetes in Pregnancy
https://doi.org/10.1371/journal.pone.0232664.t001
Table 2. Estimated risk of sociodemographic maternal characteristics for HIP.
Characteristics HIP Control RR (95%CI)
Maternal age (years)
< 25 56 (37.3) 481 (56.1) Ref.
� 25 94 (62.7) 377 (43.9) 1.91 [0.85–4.33]
Ethnicity
White 61 (40.7) 354 (41.3) Ref.
Non-white 89 (59.3) 504 (58.7) 1.02 [0.70–1.50]
Marital status(1)
With a partner 117 (78.5) 621 (72.5) Ref.
Without a partner 32 (21.5) 235 (27.5) 0.76 [0.48–1.20]
Schooling (years)
< 12 97 (64.7) 568 (66.2) Ref.
� 12 53 (35.3) 290 (33.8) 1.06 [0.74–1.51]
Annual Family Income (US$)
Up to 3000 6 (4.0) 37 (4.3) 0.91 [0.49–1.70]
3000 to 6000 75 (50.0) 438 (51.0) 0.96 [0.67–1.37]
Above 6000 69 (46.0) 383 (44.6) Ref.
Source of prenatal care
Entirely public 132 (88.0) 728 (84.8) 1.26 [0.90–1.76]
Private/insurance/mixed 18 (12.0) 130 (15.2) Ref.
Total 150 858
HIP = Hyperglycemia in Pregnancy
(1) Missing = 3 cases
https://doi.org/10.1371/journal.pone.0232664.t002
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women, some recent studies also demonstrated the same association [10–12,24,25]. Therefore,
the current literature supports our assertion that overweight or obesity before 21 weeks of ges-
tation is an independent risk factor for the development of HIP (GDM or DIP) in nulliparous
Brazilian women.
Table 3. Estimated risk of maternal lifestyle habits and characteristics for HIP.
Characteristics HIP Controls RR (95%CI)
Mother history of GDM (1)
Yes 8 (6.0) 27 (3.4) 1.63 [0.80–3.33]
No 125 (94.0) 765 (96.6) Ref.
Family history of DM
Yes 47 (31.3) 152 (17.7) 1.86 [1.50–2.30]
No 103 (68.7) 706 (82.3) Ref.
Smoking
No smoking 138 (92.0) 793 (92.4) Ref.
Ceased during pregnancy/current smoker 12 (8.0) 65 (7.6) 1.05 [0.41–2.69]
Alcohol drinking (2)
No alcohol 111 (86.7) 617 (81.8) Ref.
Ceased during pregnancy/current drinker 17 (3.3) 137 (18.2) 0.72 [0.48–1.09]
Previous abortion
Yes 17 (11.3) 97 (11.3) 1.00 [0.39–2.57]
No 133 (88.7) 761 (88.7) Ref.
WG/week (kg)– 20 to 27 weeks (3)
<Q 1 (g) 42 (33.1) 174 (24.2) 1.37 [0.77–2.43]
Q1-Q2 (g) 29 (22.8) 175 (24.3) Ref.
Q2-Q3 (g) 31 (24.4) 185 (25.7) 1.01 [0.65–1.56]
�Q3 (g) 25 (19.7) 186 (25.8) 0.83 [0.48–1.45]
Body Mass Index at enrollment#
Underweight (< 21.5 kg/m2) 12 (8.0) 150 (17.5) 0.64 [0.17–2.40]
Normal weight (21.5–26.2) 47 (31.3) 356 (41.5) Ref.
Overweight (26.3–30.9) 46 (30.7) 218 (25.4) 1.49 [1.27–1.76]
Obesity (> 30.9 kg/m2) 45 (30.0) 134 (15.6) 2.16 [1.57–2.96]
Any previous maternal disorder�
No 103 (68.7) 702 (81.8) Ref.
Yes 47 (31.3) 156 (18.2) 1.81 [1.05–3.13]
Blood pressure (BP) at 20th week
BP� 140 x 90 mmHg 9 (6.0) 28 (3.3) 168 [0.88–3.19]
BP < 140 x 90 mmHg 141 (94.0) 830 (96.7) Ref.
Blood pressure (BP) at 20th week
BP� 130 x 85 mmHg 21 (14.0) 87 (10.1) 1.36 [0.87–2.11]
BP < 130 x 85 mmHg 129 (86.0) 771 (89.9) Ref.
Total 150 858
HIP = Hyperglycemia in Pregnancy; GDM = Gestational Diabetes Mellitus; DM = Diabetes Mellitus; WG = weight
gain; SBP = Systolic Blood Pressure; DBP = Diastolic Blood Pressure
�Polycystic Ovarian Syndrome (POS) OR Thyroid dysfunctions OR Previous hypertensive disorder without
medication
(1) Missing = 83
(2) Missing = 126
(3) Missing = 161 cases
https://doi.org/10.1371/journal.pone.0232664.t003
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Table 4. Maternal and neonatal outcomes associated with HIP.
Outcomes HIP Controls RR (95%CI)
Mother
Mode of delivery
Vaginal 70 (46.7) 465 (54.2) Ref.
C-section with labor 40 (26.7) 197 (23.0) 1.30 [0.69–2.42]
C-section without labor 40 (26.7) 196 (22.8) 1.29 [0.90–1.86]
Preeclampsia or eclampsia
No 137 (91.3) 793 (92.4) Ref.
Yes 13 (8.7) 65 (7.6) 1.13 [0.65–1.98]
Maternal complications after delivery� 8 (5.3) 33 (3.8) 1.33 [0.32–5.49]
Length of postpartum hospitalization (1)
1–3 days 129 (86.0) 773 (90.2) Ref.
4–6 days 20 (13.3) 66 (7.7) 1.63 [0.96–2.76]
� 7 days 1 (0.7) 18 (2.1) 0.37 [0.02–5.43]
Newborn
Mean (SD) birthweight (g) 3172.72 (556.73) 3109.89 (601.44) p = 0.395; Dif = 62.83 [-120.52–246.19]
Gestational age at birth (weeks)
< 34 5 (3.3) 35 (4.1) 0.84 [0.07–8.53]
34–36 12 (8.0) 59 (6.9) 1.14 [0.44–2.94]
� 37 133 (88.7) 764 (89.0) Ref.
Adequacy of birthweight to GA (2)
SGA (birthweight < P10) 18 (12.0) 115 (13.4) 0.91 [0.48–1.70]
AGA (P10 < birthweight < P90) 114 (76.0) 649 (75.7) Ref.
LGA (birthweight > P90) 18 (12.0) 93 (10.9) 1.09 [0.56–2.10]
Macrosomia (birthweight � 4000g)(1) 7 (4.7) 35 (4.1) 1.12 [0.57–2.20
Fetal death – 3 (0.3) –
Apgar score– 5th minute < 7(2) 3 (2.0) 14 (1.7) 1.16 [0.26–5.20]
Need of intubation(3) 2 (1.3) 20 (2.4) 0.60 [0.04–9.14]
NICU admission 29 (19.3) 126 (14.7) 1.32 [0.92–1.89]
NICU indications†(4) 6 (20.7) 30 (23.8) 1.16 [0.41–3.30]
NICU length of admission(4)
1–3 days 13 (44.8) 51 (40.5) Ref.
4–6 days 7 (24.1) 16 (12.7) 1.50 [0.29–7.82]
� 7 days 9 (31.0) 59 (46.8) 0.65 [0.19–2.19]
Phototherapy for jaundice(5) 37 (25.0) 169 (19.9) 1.28 [0.84–1.94]
Major fetal malformation(6) 2 (1.3) 13 (1.5) 0.896 [0.31–2.59]
Neonatal Near Miss‡(7) 8 (5.3) 38 (4.4) 1.18 [0.28–4.89]
Neonatal death – 7 (0.8) –
Any adverse neonatal HIP outcome# 65 (43.3) 330 (38.5) 1.19 [0.93–1.51]
Total 150 858
HIP = Hyperglycemia in Pregnancy; GA = Gestational Age; SGA = Small for Gestational Age; AGA = Adequate for Gestational Age; LGA = Large for Gestational Age;
NCIU = Neonatal Care Intensive Unit; PPH = Postpartum hemorrhage
�Maternal complications after delivery = Severe sepsis OR Sepsis OR PPH OR Endometritis OR Hysterectomy due to hemorrhage or infection
†NCIU indications = respiratory distress or hypoglycemia or asphyxia or congenital abnormality
‡Neonatal Near Miss = Apgar 5th min < 7 OR Birthweight < 1750g OR Gestational age < 33 weeks
#Any adverse neonatal HIP outcome = Gestational age � 37 weeks OR LGA OR Macrosomia OR Apgar 5th min < 7 OR Need of intubation OR NICU OR Phototherapy
for jaundice
(1) Missing = 1
(2) Missing = 43
(3) Missing = 10
(4) Missing = 853 (No NICU admission)
(5) Missing = 11
(6) Missing = 0, after considering 632 missing values as not
(7) Missing = 0, after considering 962 missing values as not
https://doi.org/10.1371/journal.pone.0232664.t004
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In general, maternal glucose control began with medical nutrition therapy (MNT), physical
activity, and weight control. Insulin treatment was initiated whenever glycemic goals
(FPG< 95 mg/dL and a 2h postprandial glucose test< 120 mg/dL) were not met through
MNT and regular exercise [5,33]. Although evidence supports the efficacy and short-term
safety of oral anti-diabetic agents, these drugs do cross the placenta and data on long-term
effects are lacking [34]. The Brazilian drug safety regulatory agency (ANVISA) has not yet
released the oral anti-diabetic agents for use in pregnancy. Insulin would be the pharmacologi-
cal option for maternal glucose control in Brazil.
In our study, about 40% (58/150) of the HIP cases did not receive treatment. Of those
treated, a lower proportion of women (21.7%) received diet and exercise, and pharmacological
therapy. Both insulin and metformin were the predominant drugs indicated (78.3%). Regard-
less of this unsatisfactory scenario, perinatal results were statistically similar in HIP and control
groups. Nevertheless, these results were unexpected. The limited number of cases in the HIP
group, and diagnostic criteria used, in association with the high prevalence of overweight and
obese women in the control group may explain this issue.
According to the literature, all these possibilities could mask the expected differences in
perinatal outcomes. In IADPSG protocol studies, the small sample size was used to explain the
increasing incidence of GDM (10 to 25%) and limited effect on perinatal results [35–38]. Over-
weight or obesity alone has been associated with the risk of developing GDM and Metabolic
Syndrome (MetS). HOMA-IR levels increased, producing a pronounced effect on excessive
fetal growth, irrespective of maternal glucose status [22,39,40]. Thus, bias could occur in peri-
natal outcomes in non-diabetic pregnancies.
Strengths and limitations
In our study we evaluated healthy nulliparous Brazilian women in a prospective multicenter
cohort from five public maternity hospitals, corresponding to a multi-regional and mixed pop-
ulation in an upper-middle income country. In addition, our study highlighted some problems
in the quality of diabetes care in pregnancy. Our results may contribute to the identification of
risk factor for HIP in nulliparous women which were not done previously worldwide, espe-
cially in Brazil where pertinent data are not available.
Our study has some limitations. Pregestational weight records are lacking, the sample size
was not specifically calculated for HIP outcomes and glucose control was not standardized in
collaborating centers. Nevertheless, our study reflected local protocols and the reality of obstet-
ric referral centers.
To the best of our knowledge, this was a pioneer study in Brazil. Other studies with a larger
sample size may confer increased statistical power to the results and identify new risk factors
for hyperglycemia in healthy nulliparous pregnant women.
Conclusions
There was a high incidence of HIP (14.9%) in a nulliparous Brazilian cohort, with 94.7% of the
cases due to GDM. A family history of DM, overweight or obesity and some previous clinical
Table 5. Factors independently associated with HIP by multivariate analysis.
Characteristics RRadj (95%CI)
Body Mass Index at enrollment (overweight or obesity) 1.87 [1.66–2.10]
Family history of DM 1.71 [1.37–2.15]
- Variables included in the model: outcome is HIP; the predictors are all variables from Tables 2 and 3
https://doi.org/10.1371/journal.pone.0232664.t005
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conditions were associated with HIP. However, only a BMI� 26.3Kg/m2 at study enrollment
and a family history of DM were shown to be independent risk factors for HIP. While there is
no incontrovertible evidence to support universal screening, a family history of DM and a
BMI� 26.3Kg/m2 (until 19–21 weeks of gestation) may be used as selective markers for Brazil-
ian nulliparous women. This strategy will potentially ameliorate the diagnostic performance of
HIP in low-resource settings where universal screening is not easily available. Taking into
account the scarcity of results in nulliparous women, our findings may contribute to deter-
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